NCT01790165已完成2 期
A Phase II Open Label Multiple-Dose Study of the Safety and Pharmacokinetics of TDT 067 Under Conditions of Maximal Use in Subjects With Distal Subungual Onychomycosis of the Toenails
Celtic Pharma Development Services0 个研究点目标入组 27 人开始时间: 2009年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 27
- 主要终点
- PK
研究概览
简要总结
The aim of this study is to establish a clinical bridge to Lamisil® tablets by conducting a clinical pharmacokinetic (PK) study comparing the systemic exposure of a Lamisil® tablet with that of with TDT 067 under maximal use conditions.
Under maximal use conditions in onychomycotic subjects, the aim is to confirm that there are significantly lower plasma levels of terbinafine and its major metabolites after a topical administration of TDT 067 for 28 days in comparison with a single oral 250 mg Lamisil® tablet.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Screening
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must be between 18 and 65 years of age inclusive, of any race, and of either sex.
- •Male subjects only: Male subjects must use a reliable form of contraception during their participation in the trial and for 3 months after their last dose of study drug.
- •Female subjects only: Either of non-childbearing potential (i.e. either surgically sterilized or post menopausal) or must be using adequate contraception, have a negative pregnancy test prior to start of dosing, and must agree to continue to use this method of contraception until 3 months after the last dose. Acceptable contraceptive methods are oral contraceptive, IUD, or diaphragm with spermicide (unless anatomically sterile).
- •Subjects must be in good general health as confirmed by a medical history and physical examination.
- •Subjects must have 2 big toes with nails that have the potential to be clipped to provide nail samples.
- •Subjects must have clinically diagnosed distal subungual onychomycosis of the toenails; at least 5 nails in total must present with onychomycotic signs (onycholysis, subungual hyperkeratosis) including extensive involvement (≥50%) of both large nails and mycological confirmation (positive KOH microscopy) from 1 of the large nails.
- •Subject must sign a statement of informed consent.
- •Subjects must be able to understand the requirements of the study, abide by the restriction, and return for all of the required examinations
排除标准
- •Subjects lacking any toes.
- •Subjects with known hypersensitivity to terbinafine or any of the excipients in the TDT
- •Subjects with symptomatic tinea pedis requiring treatment.
- •Subjects with any medical, neurological, or psychiatric conditions that in the opinion of the Investigator would make the subject unsuitable for enrollment onto the study.
- •Subjects with chronic or active liver disease, as well as subjects with elevated liver function tests above normal for the testing laboratory.
- •Subjects with renal impairment (creatinine clearance ≤50 mL/min).
- •Subjects who have received terbinafine tablets within 12 months or topical terbinafine (cream, solution/spray, or gel) within 6 months prior to screening visit; subjects who have received other oral antifungals within 4 months or other topical antifungals within 1 month.
- •Subjects who have participated within the previous 3 months in a clinical trial for the systemic or topical treatment of onychomycosis.
- •Subjects being treated with rifampin or cimetidine.
- •Subjects being treated with an investigational drug within 1 month prior to study start.
- •Subjects with psoriasis or history of psoriasis.
- •Subjects with nail dystrophy or other nail abnormalities other than onychomycosis.
- •Subjects with serious concurrent disease that might prevent completion of the trial.
- •Subjects who are pregnant (confirmed by pregnancy test) or who plan to become pregnant within the study timeframe or who are nursing.
- •Subjects who cannot read, understand, or sign the informed consent form or the instructions for applying and removing the study formulations.
- •Subjects who cannot apply the product to their toenails.
- •Subjects who do not wish to provide nail clippings.
- •Subjects who cannot or will not provide adequate blood and urine samples.
- •Subjects using any nail polish products or other nail cosmetic products on any of the toenails designated for treatment within 7 days prior to the start of treatment and who are unwilling to discontinue use of these products for the duration of this study.
研究组 & 干预措施
TDT067
Experimental
Active treatment
干预措施: TDT067 and Lamisil (Drug)
结局指标
主要结局
PK
时间窗: 35 days
Cmax, Tmax, AUC0-12, AUC0-24, Cmax Ratio (day 28/day 35) were evaluated
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)Multidrug Resistant TuberculosisNCT01859923Otsuka Pharmaceutical Development & Commercialization, Inc.37
已完成
2 期
Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)Alpha 1-Antitrypsin DeficiencyNCT03946449Arrowhead Pharmaceuticals16
终止
1 期
A Study of Varlilumab and Atezolizumab in Patients With Advanced CancerCarcinoma, Renal CellKidney DiseasesKidney NeoplasmsUrogenital NeoplasmsUrologic DiseasesUrologic NeoplasmsNeoplasms by Histologic TypeNeoplasmsClear-cell Metastatic Renal Cell CarcinomaTriple Negative Breast CancerHead and Neck CancerMelanomaBladder CancerNon-small Cell Lung CancerNCT02543645Celldex Therapeutics18
已完成
2 期
A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)MZLNCT03797456Beijing InnoCare Pharma Tech Co., Ltd.111
已完成
1 期
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)Cancer of the BreastTriple Negative Breast CancerER+ Breast CancerBreast CancerMetastatic Breast CancerMale Breast CancerAdvanced Breast CancerNCT02580448Innocrin Pharmaceutical175